

HB 2257-3
(LC 633)
2/11/19 (SCT/ps)

Requested by HOUSE COMMITTEE ON HEALTH CARE (at the request of Governor Kate Brown)

**PROPOSED AMENDMENTS TO
HOUSE BILL 2257**

1 On page 1 of the printed bill, line 2, after “drugs;” insert “creating new
2 provisions; amending ORS 431A.850, 431A.855, 431A.860, 431A.865, 431A.867
3 and 431A.898;”.

4 In line 11, after the period insert “The department may collaborate with
5 counties that operate local correctional facilities, as defined in ORS 169.005,
6 to collect data regarding persons in the custody of local correctional facili-
7 ties in the counties, in particular persons experiencing substance use disor-
8 ders, including opioid and opiate addiction.”.

9 Delete lines 12 through 21.

10 In line 22, delete “(3)(a)” and insert “(2)(a)” and after “192.245” delete
11 “based”.

12 On page 2, delete line 1.

13 In line 2, delete “section (2) of this section,”.

14 In line 11, after “to” delete the rest of the line and insert “advise the
15 authority on the authority’s establishment of”.

16 In line 12, delete “ish”.

17 After line 15, insert:

18 “(2) When considering requirements under this section, the advisory group
19 shall:

20 “(a) Solicit input from stakeholders, including state agencies, unions re-
21 presenting substance use disorder treatment providers and others; and

1 “(b) Consider relevant factors, including but not limited to the geographic
2 accessibility of treatment, culturally appropriate treatment options, the lan-
3 guage needs of potential treatment patients and the needs of substance use
4 disorder treatment providers.

5 “(3) The advisory group shall research and determine how to maximize
6 all sources of federal funding that are available for treatment programs de-
7 scribed in this section.

8 “(4) The advisory group may adopt rules to carry out this section.”

9 In line 16, delete “(2)” and insert “(5)”.

10 Delete lines 22 through 28 and insert:

11 **“SECTION 7. (1) The Oregon Health Authority shall prohibit coor-
12 dinated care organizations and public payers of health insurance, when
13 reimbursing the cost of medication-assisted treatment for treating
14 substance use disorders, including opioid and opiate addiction, from
15 requiring prior authorization of payment during the first 30 days of
16 medication-assisted treatment.**

17 **“(2) The authority may adopt rules to carry out this section.**

18 **“SECTION 8. Section 7 of this 2019 Act applies to the provision of
19 treatment services that begins on or after the operative date specified
20 in section 21 (1) of this 2019 Act.”**

21 On page 3, after line 17, insert:

22 “(3) Sterile needles and syringes and other items provided by a syringe
23 service program may not be considered ‘drug paraphernalia,’ as that term is
24 defined in ORS 475.525.”

25 Delete lines 20 through 26 and insert:

26 **“SECTION 15. ORS 431A.850, as amended by section 14, chapter 61,
27 Oregon Laws 2018, is amended to read:**

28 **“ORS 431A.850. As used in ORS 431A.855 to 431A.900:**

29 **“(1) ‘Dental director’ means a dentist, as defined in ORS 679.010,
30 employed by a coordinated care organization, dental clinic or office,**

1 **or a system of dental clinics or offices, for the purpose of overseeing**
2 **the operations of the dental clinic or office, or the system of dental**
3 **clinics or offices, and ensuring the delivery of quality dental care**
4 **within the clinic, office or system.**

5 “[1] (2) ‘Dispense’ and ‘dispensing’ have the meanings given those terms
6 in ORS 689.005.

7 “[2] (3) ‘Drug outlet’ has the meaning given that term in ORS 689.005.

8 “[3] (4) ‘Health professional regulatory board’ means a health profes-
9 sional regulatory board, as defined in ORS 676.160, the Long Term Care Ad-
10 ministrators Board, the Board of Licensed Dietitians and the Behavior
11 Analysis Regulatory Board.

12 “[4] (5) ‘Medical director’ means a physician employed by a **coordinated**
13 **care organization**, hospital, health care clinic or system of hospitals or
14 health care clinics for the purposes of overseeing the operations of the **co-**
15 **ordinated care organization**, hospital, clinic or system and ensuring the
16 delivery of quality health care within the **coordinated care organization**,
17 hospital, clinic or system.

18 “[5] (6) ‘Pharmacist’ means:

19 “(a) A pharmacist as defined in ORS 689.005; or

20 “(b) An individual licensed to practice pharmacy in another state, if the
21 requirements for licensure are similar, as determined by the Oregon Health
22 Authority, to the requirements for being licensed as a pharmacist as defined
23 in ORS 689.005.

24 “[6] (7) ‘Pharmacy director’ means a pharmacist employed by a **coordi-**
25 **nated care organization**, pharmacy or system of pharmacies for the pur-
26 poses of overseeing the operations of the **coordinated care organization**,
27 pharmacy or system and ensuring the delivery of quality pharmaceutical care
28 within the **coordinated care organization**, pharmacy or system.

29 “[7] (8) ‘Practitioner’ means:

30 “(a) A practitioner as defined in ORS 689.005; or

1 “(b) An individual licensed to practice a profession in another state, if the
2 requirements for licensure are similar, as determined by the authority, to the
3 requirements for being licensed as a practitioner as defined in ORS 689.005.

4 “[8] (9) ‘Prescription’ has the meaning given that term in ORS 475.005.

5 “[9] (10) ‘Prescription drug’ has the meaning given that term in ORS
6 689.005.

7 **“SECTION 16.** ORS 431A.855, as amended by section 8, chapter 45,
8 Oregon Laws 2018, is amended to read:

9 “431A.855. (1)(a) The Oregon Health Authority, in consultation with the
10 Prescription Monitoring Program Advisory Commission, shall establish and
11 maintain a prescription monitoring program for monitoring and reporting:

12 “(A) Prescription drugs dispensed by pharmacies licensed by the State
13 Board of Pharmacy that are classified in schedules II through IV under the
14 federal Controlled Substances Act, 21 U.S.C. 811 and 812, as modified by the
15 board by rule under ORS 475.035; and

16 “(B) Prescribed **gabapentin and** naloxone dispensed by pharmacies.

17 “(b)(A) To fulfill the requirements of this subsection, the authority shall
18 establish, maintain and operate an electronic system to monitor and report
19 drugs described in paragraph (a) of this subsection that are dispensed by
20 prescription.

21 “(B) The electronic system must:

22 “(i) Operate and be accessible by practitioners and pharmacies 24 hours
23 a day, seven days a week; and

24 “(ii) Allow practitioners to register as required under section 7, chapter
25 45, Oregon Laws 2018, and to apply for access to the electronic system in
26 accordance with rules adopted by the authority under subsection (2) of this
27 section.

28 “(C) The authority may contract with a state agency or private entity to
29 ensure the effective operation of the electronic system.

30 “(2) In consultation with the commission, the authority shall adopt rules

1 for the operation of the electronic prescription monitoring program estab-
2 lished under subsection (1) of this section, including standards for:

3 “(a) Reporting data;

4 “(b) Providing maintenance, security and disclosure of data;

5 “(c) Ensuring accuracy and completeness of data;

6 “(d) Complying with the federal Health Insurance Portability and Ac-
7 countability Act of 1996 (P.L. 104-191) and regulations adopted under that
8 law, including 45 C.F.R. parts 160 and 164, federal alcohol and drug treat-
9 ment confidentiality laws and regulations adopted under those laws, includ-
10 ing 42 C.F.R. part 2, and state health and mental health confidentiality laws,
11 including ORS 179.505, 192.517 and 192.553 to 192.581;

12 “(e) Ensuring accurate identification of persons or entities requesting in-
13 formation from the database;

14 “(f) Accepting printed or nonelectronic reports from pharmacies that do
15 not have the capability to provide electronic reports;

16 “(g) Notifying a patient, before or when a drug classified in schedules II
17 through IV is dispensed to the patient, about the prescription monitoring
18 program and the entry of the prescription in the electronic system; and

19 “(h) Registering practitioners with the electronic system.

20 “(3) The authority shall submit an annual report to the commission re-
21 garding the prescription monitoring program established under this section.

22 **“SECTION 17.** ORS 431A.860 is amended to read:

23 “431A.860. (1) Not later than 72 hours after dispensing a prescription drug
24 that is subject to the prescription monitoring program established under ORS
25 431A.855, a pharmacy shall electronically report to the Oregon Health Au-
26 thority:

27 “(a) If the prescription drug is classified in schedules II through IV under
28 the federal Controlled Substances Act, 21 U.S.C. 811 and 812, as modified
29 by the State Board of Pharmacy by rule under ORS 475.035, the name, ad-
30 dress, phone number, date of birth and sex of the patient for whom the pre-

1 prescription drug was prescribed;

2 “(b) The identity of the pharmacy that dispensed the prescription drug
3 and the date on which the prescription drug was dispensed;

4 “(c) The identity of the practitioner who prescribed the prescription drug
5 and the date on which the prescription drug was prescribed;

6 “(d) The national drug code number for the prescription drug;

7 “(e) The prescription number assigned to the prescription drug;

8 “(f) The quantity of the prescription drug dispensed;

9 “(g) The number of days for which the prescription drug was dispensed;

10 [*and*]

11 “(h) The number of refills of the prescription authorized by the practi-
12 tioner and the number of the refill that the pharmacy dispensed; **and**

13 **“(i) The diagnosis code used by the practitioner and the reason for
14 the prescription.**

15 “(2)(a) Notwithstanding subsection (1) of this section, the authority may
16 not:

17 “(A) Require the reporting of prescription drugs administered directly to
18 a patient or dispensed pursuant to ORS 127.800 to 127.897;

19 “(B) Collect or use Social Security numbers in the prescription monitor-
20 ing program; or

21 “(C) Disclose under ORS 431A.865 (2)(a) the sex of the patient for whom
22 a drug was prescribed.

23 “(b) The sex of the patient for whom a drug was prescribed may be dis-
24 closed only for the purpose of research or epidemiological study under ORS
25 431A.865 (2)(b).

26 “(3) Upon receipt of the data reported pursuant to subsection (1) of this
27 section, the authority shall record the data in the electronic system estab-
28 lished under ORS 431A.855.

29 “(4)(a) The authority may, for good cause as determined by the authority,
30 grant a pharmacy a waiver of the requirement that the information to be

1 reported under subsection (1) of this section be submitted electronically. The
2 waiver must state the format, method and frequency of the alternate non-
3 electronic submissions from the pharmacy and the duration of the waiver.

4 “(b) As used in this subsection, ‘good cause’ includes financial hardship.

5 “(5) This section does not apply to pharmacies in institutions as defined
6 in ORS 179.010.

7 **“SECTION 18.** ORS 431A.865 is amended to read:

8 “431A.865. (1)(a) Except as provided under subsection (2) of this section,
9 prescription monitoring information submitted under ORS 431A.860 to the
10 prescription monitoring program established in ORS 431A.855:

11 “(A) Is protected health information under ORS 192.553 to 192.581.

12 “(B) Is confidential and not subject to disclosure under ORS 192.311 to
13 192.478.

14 “(b) Except as provided under subsection (2)(a)(H) of this section, pre-
15 scription monitoring information submitted under ORS 431A.860 to the pre-
16 scription monitoring program may not be used to evaluate a practitioner’s
17 professional practice.

18 “(2)(a) To the extent that the law or regulation is applicable to the pre-
19 scription monitoring program, if a disclosure of prescription monitoring in-
20 formation, other than the sex of a patient for whom a drug was prescribed,
21 complies with the federal Health Insurance Portability and Accountability
22 Act of 1996 (P.L. 104-191) and regulations adopted under that law, including
23 45 C.F.R. parts 160 and 164, federal alcohol and drug treatment
24 confidentiality laws and regulations, including 42 C.F.R. part 2, and state
25 health and mental health confidentiality laws, including ORS 179.505, 192.517
26 and 192.553 to 192.581, the Oregon Health Authority shall disclose the in-
27 formation:

28 “(A) To a practitioner or pharmacist, or, if a practitioner or pharmacist
29 authorizes the authority to disclose the information to a member of the
30 practitioner’s or pharmacist’s staff, to a member of the practitioner’s or

1 pharmacist's staff. If a practitioner or pharmacist authorizes disclosing the
2 information to a member of the practitioner's or pharmacist's staff under this
3 subparagraph, the practitioner or pharmacist remains responsible for the use
4 or misuse of the information by the staff member. To receive information
5 under this subparagraph, or to authorize the receipt of information by a staff
6 member under this subparagraph, a practitioner or pharmacist must certify
7 that the requested information is for the purpose of evaluating the need for
8 or providing medical or pharmaceutical treatment for a patient to whom the
9 practitioner or pharmacist anticipates providing, is providing or has provided
10 care.

11 “(B) To a **dental director**, medical director or pharmacy director, or, if
12 a **dental director**, medical director or pharmacy director authorizes the au-
13 thority to disclose the information to a member of the **dental director's**,
14 medical director's or pharmacy director's staff, to a member of the **dental**
15 **director's**, medical director's or pharmacy director's staff. If a **dental di-**
16 **rector**, medical director or pharmacy director authorizes disclosing the in-
17 formation to a member of the **dental director's**, medical director's or
18 pharmacy director's staff under this subparagraph, the **dental director**,
19 medical director or pharmacy director remains responsible for the use or
20 misuse of the information by the staff member. To receive information under
21 this subparagraph, or to authorize the receipt of information by a staff
22 member under this subparagraph[,]:

23 “(i) **A dental director must certify that the requested information**
24 **is for the purposes of overseeing the operations of a coordinated care**
25 **organization, dental clinic or office, or a system of dental clinics or**
26 **offices, and ensuring the delivery of quality dental care within the**
27 **coordinated care organization, clinic, office or system.**

28 “(ii) A medical director must certify that the requested information is for
29 the purposes of overseeing the operations of a **coordinated care organiza-**
30 **tion**, hospital, health care clinic or system of hospitals or health care clinics

1 and ensuring the delivery of quality health care within the **coordinated**
2 **care organization**, hospital, clinic or system. [*To receive information under*
3 *this subparagraph, or to authorize the receipt of information by a staff member*
4 *under this subparagraph,*]

5 “(iii) A pharmacy director must certify that the requested information is
6 for the purposes of overseeing the operations of a **coordinated care or-**
7 **ganization**, pharmacy or system of pharmacies and ensuring the delivery of
8 quality pharmaceutical care within the **coordinated care organization**,
9 pharmacy or system.

10 “(C) In accordance with subparagraphs (A) and (B) of this paragraph, to
11 an individual described in subparagraphs (A) and (B) of this paragraph
12 through a health information technology system that is used by the individ-
13 ual to access information about patients if:

14 “(i) The individual is authorized to access the information in the health
15 information technology system;

16 “(ii) The information is not permanently retained in the health informa-
17 tion technology system, except for purposes of conducting audits and main-
18 taining patient records; and

19 “(iii) The health information technology system meets any privacy and
20 security requirements and other criteria, including criteria required by the
21 federal Health Insurance Portability and Accountability Act, established by
22 the authority by rule.

23 “(D) To a practitioner in a form that catalogs all prescription drugs pre-
24 scribed by the practitioner according to the number assigned to the practi-
25 tioner by the Drug Enforcement Administration of the United States
26 Department of Justice.

27 “(E) To the Chief Medical Examiner or designee of the Chief Medical
28 Examiner, for the purpose of conducting a medicolegal investigation or
29 autopsy.

30 “(F) To designated representatives of the authority or any vendor or

1 contractor with whom the authority has contracted to establish or maintain
2 the electronic system established under ORS 431A.855.

3 “(G) Pursuant to a valid court order based on probable cause and issued
4 at the request of a federal, state or local law enforcement agency engaged
5 in an authorized drug-related investigation involving a person to whom the
6 requested information pertains.

7 “(H) To a health professional regulatory board that certifies in writing
8 that the requested information is necessary for an investigation related to
9 licensure, license renewal or disciplinary action involving the applicant,
10 licensee or registrant to whom the requested information pertains.

11 “(I) Pursuant to an agreement entered into under ORS 431A.869.

12 “(b) The authority may disclose information from the prescription moni-
13 toring program that does not identify a patient, practitioner or drug outlet:

14 “(A) For educational, research or public health purposes;

15 “(B) For the purpose of educating practitioners about the prescribing of
16 opioids and other controlled substances;

17 “(C) To a health professional regulatory board;

18 “(D) To a local public health authority, as defined in ORS 431.003; or

19 “(E) To officials of the authority who are conducting special
20 epidemiologic morbidity and mortality studies in accordance with ORS
21 413.196 and rules adopted under ORS 431.001 to 431.550 and 431.990.

22 “(c) The authority shall disclose information relating to a patient main-
23 tained in the electronic system established under ORS 431A.855 to that pa-
24 tient at no cost to the patient within 10 business days after the authority
25 receives a request from the patient for the information.

26 “(d)(A) A patient may request the authority to correct any information
27 related to the patient that is maintained in the electronic system established
28 under ORS 431A.855 that is erroneous. The authority shall grant or deny a
29 request to correct information within 10 business days after the authority
30 receives the request. If a request to correct information cannot be granted

1 because the error occurred at the pharmacy where the information was
2 inputted, the authority shall inform the patient that the information cannot
3 be corrected because the error occurred at the pharmacy.

4 “(B) If the authority denies a patient’s request to correct information
5 under this paragraph, or fails to grant a patient’s request to correct infor-
6 mation under this paragraph within 10 business days after the authority re-
7 ceives the request, the patient may appeal the denial or failure to grant the
8 request. Upon receiving notice of an appeal under this subparagraph, the
9 authority shall conduct a contested case hearing as provided in ORS chapter
10 183. Notwithstanding ORS 183.450, the authority has the burden in the con-
11 tested case hearing of establishing that the information is correct.

12 “(e) The information in the prescription monitoring program may not be
13 used for any commercial purpose.

14 “(f) In accordance with ORS 192.553 to 192.581 and federal laws and reg-
15 ulations related to privacy, any person authorized to prescribe or dispense
16 a prescription drug who is entitled to access a patient’s prescription moni-
17 toring information may discuss the information with or release the informa-
18 tion to other health care providers involved with the patient’s care for the
19 purpose of providing safe and appropriate care coordination.

20 “(3)(a) The authority shall maintain records of the information disclosed
21 through the prescription monitoring program including:

22 “(A) The identity of each person who requests or receives information
23 from the program and any organization the person represents;

24 “(B) The information released to each person or organization; and

25 “(C) The date and time the information was requested and the date and
26 time the information was provided.

27 “(b) Records maintained as required by this subsection may be reviewed
28 by the Prescription Monitoring Program Advisory Commission.

29 “(4) Information in the prescription monitoring program that identifies
30 an individual patient must be removed no later than three years from the

1 date the information is entered into the program.

2 “(5) The authority shall notify the Attorney General and each individual
3 affected by an improper disclosure of information from the prescription
4 monitoring program of the disclosure.

5 “(6)(a) If the authority or a person or entity required to report or au-
6 thorized to receive or release prescription information under this section vi-
7 olates this section or ORS 431A.860 or 431A.870, a person injured by the
8 violation may bring a civil action against the authority, person or entity and
9 may recover damages in the amount of \$1,000 or actual damages, whichever
10 is greater.

11 “(b) Notwithstanding paragraph (a) of this subsection, the authority and
12 a person or entity required to report or authorized to receive or release
13 prescription information under this section are immune from civil liability
14 for violations of this section or ORS 431A.860 or 431A.870 unless the au-
15 thority, person or entity acts with malice, criminal intent, gross negligence,
16 recklessness or willful intent.

17 “(7) Nothing in ORS 431A.855 to 431A.900 requires a practitioner or
18 pharmacist who prescribes or dispenses a prescription drug to obtain infor-
19 mation about a patient from the prescription monitoring program. A practi-
20 tioner or pharmacist who prescribes or dispenses a prescription drug may
21 not be held liable for damages in any civil action on the basis that the
22 practitioner or pharmacist did or did not request or obtain information from
23 the prescription monitoring program.

24 “(8) The authority shall, at regular intervals, ensure compliance of a
25 health information technology system described in subsection (2) of this
26 section with the privacy and security requirements and other criteria estab-
27 lished by the authority under subsection (2) of this section.

28 **“SECTION 19.** ORS 431A.867 is amended to read:

29 “431A.867. (1) The Oregon Health Authority may require a person re-
30 questing prescription monitoring program information under ORS 431A.865

1 (2)(b) to enter into a data use agreement under which the person:

2 “(a) Describes the proposed use for the information;

3 “(b) Agrees to any terms and conditions imposed on transferring the in-
4 formation;

5 “(c) Agrees to any limitations imposed on using the information;

6 “(d) Agrees to any terms and conditions imposed on keeping the infor-
7 mation; and

8 “(e) Agrees to destroy the information after completing the proposed use
9 for the information.

10 “(2) In determining whether to enter into an agreement under this section,
11 the authority shall:

12 “(a) [*Evaluate the merits of the request for information*] **Ensure that the**
13 **agreement will benefit the health and safety of Oregonians;**

14 “(b) Determine whether the person making the request has the technical
15 competence needed to meet any terms, conditions or limitations imposed un-
16 der subsection (1) of this section and the ability to complete the proposed
17 use for the information;

18 “(c) If the proposed use for the information involves research, ensure that
19 the proposed use has been approved by any involved institutional review
20 board; and

21 “(d) Consider any other factor that the authority determines is relevant.

22 “(3) Using the factors described in subsection (2) of this section, the au-
23 thority shall evaluate any agreement entered into under this section at least
24 once per year for the purpose of determining whether to renew the agree-
25 ment.

26 “**SECTION 20.** ORS 431A.898 is amended to read:

27 “431A.898. (1) Not less than once per year, the Oregon Health Authority,
28 in consultation with the Prescription Monitoring Program Advisory Com-
29 mission created under ORS 431A.890 and the Prescription Monitoring Pro-
30 gram Prescribing Practices Review Subcommittee established under ORS

1 431A.896, shall develop, through the use of prescription monitoring informa-
2 tion, criteria by which a practitioner may be required to receive education
3 or training on the prescribing of opioids or opiates.

4 “(2) Criteria developed under subsection (1) of this section must include:

5 “(a) Prescribing a high volume of opioids or opiates classified in schedules
6 II and III;

7 “(b) Prescribing an above-average amount of doses of opioids or opiates
8 classified in schedules II and III to a high number of patients; and

9 “(c) Simultaneously prescribing opioids or opiates classified in schedules
10 II and III with other drugs classified in schedules II and III.

11 “(3) In developing the criteria developed under subsection (1) of this sec-
12 tion, the authority must take into consideration the total quantity and vol-
13 ume of opioids and opiates classified in schedules II and III prescribed by
14 each practitioner.

15 “(4) The subcommittee may review, through the use of prescription moni-
16 toring information that does not identify a patient, a practitioner’s pre-
17 scribing history for the three years immediately preceding the date of the
18 review to determine whether a practitioner meets the criteria developed un-
19 der subsection (1) of this section.

20 “(5) After performing the review described in subsection (4) of this sec-
21 tion, the subcommittee may direct the authority to provide to a practitioner
22 who meets the criteria developed under subsection (1) of this section educa-
23 tional information about prescribing opioids and opiates, as determined ap-
24 propriate by the authority.

25 **“(6)(a) For the purposes of evaluating prescriptions made by prac-**
26 **titioners of opioids and opiates and other controlled substances, the**
27 **subcommittee may direct the authority to compare the prescriptions**
28 **described in this paragraph between similarly situated practitioners**
29 **and to provide the comparative information to practitioners who meet**
30 **criteria established by the subcommittee.**

1 **“(b) The subcommittee may adopt rules to carry out this sub-**
2 **section, including rules to establish criteria to determine to which**
3 **practitioners to provide the information described in this subsection.**

4 **“[(6)] (7) Prescription monitoring information used for purposes of this**
5 **section and the data created through the use of prescription monitoring in-**
6 **formation pursuant to this section:**

7 **“(a) Are confidential and not subject to public disclosure under ORS**
8 **192.311 to 192.478; and**

9 **“(b) Are not admissible as evidence in a civil or criminal proceeding.**

10 **“SECTION 21. (1) Sections 1 to 14 of this 2019 Act and the amend-**
11 **ments to ORS 431A.850, 431A.855, 431A.860, 431A.865, 431A.867 and**
12 **431A.898 by sections 15 to 20 of this 2019 Act become operative on**
13 **January 1, 2020.**

14 **“(2) The Department of Corrections and the Oregon Health Au-**
15 **thority may take any action before the operative date specified in**
16 **subsection (1) of this section that is necessary to enable the depart-**
17 **ment and the authority to exercise, on and after the operative date**
18 **specified in subsection (1) of this section, all of the duties, functions**
19 **and powers conferred on the department and the authority by sections**
20 **1 to 14 of this 2019 Act and the amendments to ORS 431A.850, 431A.855,**
21 **431A.860, 431A.865. 431A.867 and 431A.898 by sections 15 to 20 of this 2019**
22 **Act.”.**

23 In line 27, delete “16” and insert “22”.

24
